These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36913304)

  • 1. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
    Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
    Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.
    Ngoi NYL; Tang TY; Gaspar CF; Pavlick DC; Buchold GM; Scholefield EL; Parimi V; Huang RSP; Janovitz T; Danziger N; Levy MA; Pant S; De Armas AD; Kumpula D; Ross JS; Javle M; Rodon Ahnert J
    Oncologist; 2024 Jun; 29(6):493-503. PubMed ID: 38330461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
    Karikari CA; Mullendore M; Eshleman JR; Argani P; Leoni LM; Chattopadhyay S; Hidalgo M; Maitra A
    Mol Cancer Ther; 2005 Dec; 4(12):1860-6. PubMed ID: 16373701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
    Basin MF; Bratslavsky G; Nahhas N; Basnet A; Goldberg H; Necchi A; Sokol ES; Ramkissoon SH; Huang RSP; Ross JS; Jacob JM
    Urol Oncol; 2023 Feb; 41(2):109.e15-109.e22. PubMed ID: 36443178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
    Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
    Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
    de Oliveira SF; Ganzinelli M; Chilà R; Serino L; Maciel ME; Urban Cde A; de Lima RS; Cavalli IJ; Generali D; Broggini M; Damia G; Ribeiro EM
    PLoS One; 2016; 11(1):e0145647. PubMed ID: 26751376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
    Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
    Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
    Chen ZH; Olopade OI; Savarese TM
    Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
    Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
    Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
    Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
    Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
    Menezes WP; Silva VAO; Gomes INF; Rosa MN; Spina MLC; Carloni AC; Alves ALV; Melendez M; Almeida GC; Silva LSD; Clara C; da Cunha IW; Hajj GNM; Jones C; Bidinotto LT; Reis RM
    Cells; 2020 Feb; 9(2):. PubMed ID: 32093414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
    Hori H; Tran P; Carrera CJ; Hori Y; Rosenbach MD; Carson DA; Nobori T
    Cancer Res; 1996 Dec; 56(24):5653-8. PubMed ID: 8971171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance.
    Gjuka D; Adib E; Garrison K; Chen J; Zhang Y; Li W; Boutz D; Lamb C; Tanno Y; Nassar A; El Zarif T; Kale N; Rakaee M; Mouhieddine TH; Alaiwi SA; Gusev A; Rogers T; Gao J; Georgiou G; Kwiatkowski DJ; Stone E
    Cancer Cell; 2023 Oct; 41(10):1774-1787.e9. PubMed ID: 37774699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.